Table 1 Main demographic and clinical characteristics of the patients with systemic sclerosis and healthy controls
Characteristics | Patients (n = 39) | Controls (n = 53) |
|---|---|---|
Female/male, n | 30/9 | 28/25 |
Age, mean ± SD | 48.4 ± 11.3 | 40.0 ± 13.7 |
Disease duration, months, mean ± SD | 95.4 ± 100.7 | |
lcSSc/dcSSc, n | 26/13 | |
Rodnan score, mean ± SD | 13.8 ± 6.8 | |
Corrected DLCOa, mean ± SD | 19.7 ± 6.7 | |
ANA patternb, n (%) | ||
Speckled | 10/34 (29.4) | |
Nucleolar | 9/34 (26.5) | |
Homogeneous | 9/34 (26.5) | |
Centromere | 16/34 (47.1) | |
Anti-Scl-70 positivity | 6/33 (18.2) | |
Organ involvement, n (%) | ||
Peripheral vascular | 16 (41.6) | |
Gastrointestinal tract | 27 (69.2) | |
Lung | 21 (53.8) | |
Heart | 16 (41.0) | |
Kidney | 4 (10.2) | |
Therapy, n/total number | ||
Prednisone | 3/39 | |
Azathioprine + prednisone | 2/39 | |
Methotrexate | 4/39 | |
D-penicillamine | 1/39 | |
Methotrexate + D-penicillamine | 1/39 | |
Methotrexate + D-penicillamine + prednisone | 1/39 | |
Hydroxychloroquine | 4/39 | |
Methotrexate + hydroxychloroquine | 1/39 | |
Only symptomatic treatment | 22/39 | |